XELOX (capecitabine plus oxaliplatin) plus bevacizumab (anti-VEGF-A antibody) with or without adoptive cell immunotherapy in the treatment of patients with previously untreated metastatic colorectal cancer: a multicenter, open-label, randomized, controlled, phase 3 trial. - Pan QZ; Zhao JJ; Liu L; Zhang DS; Wang LP; Hu WW; Weng DS; Xu X; Li YZ; Tang Y; Zhang WH; Li JY; et al. (Signal transduction and targeted therapy, 2024)